Selecting Therapy for Difficult-to-Treat Resistant Pseudomonas aeruginosa

Body:The updated guidance adds recent comparative studies of ceftazidime-avibactam vs ceftolozane-tazobactam, including data supporting a preference for ceftolozane-tazobactam in DTR P aeruginosa pneumonia, along with results from the Game Changer trial of cefiderocol.

“This is one of those situations where it can be really helpful to have local epidemiologic data to understand what is going to work best for your institution,” said Emily L. Heil, PharmD, MS, FIDP, BCIDP, AAHIVP, professor in the Department of Practice, Sciences, and Health Outcomes Research at the University of Maryland School of Pharmacy and pharmacy director of the Antimicrobial Stewardship Program at the University of Maryland Medical Center.

In this episode, Heil and Pranita D. Tamma, MD, MHS, of the Department of Pediatrics at the University of Pennsylvania School of Medicine, discuss how they prioritize available agents, why cefiderocol remains a later-line option in their practice, and the growing concern over VIM-producing P aeruginosa. Tamma also explains why the panel deliberately chose “suggest” over “recommend” throughout the document.EP. 5 Headline: Why Sulbactam-Durlobactam Is Now the Priority for Invasive CRAB InfectionsSummary: In part 5 of the series, the clinicians explain the shift toward sulbactam-durlobactam for invasive carbapenem-resistant Acinetobacter baumannii infections and how hospitals with low CRAB volume can still plan for access.Segment: 39:14–46:19